Jpmorgan Chase & CO Point Biopharma Global Inc. Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.67 - $9.71 $286,429 - $416,976	-42,943 Reduced 6.61%	607,049 $4.05 Million
Q2 2023 Aug 11, 2023	BUY	$6.86 - $10.86 $3.99 Million - $6.32 Million	581,750 Added 852.48%	649,992 $5.89 Million
Q1 2023 May 18, 2023	BUY	$6.78 - $8.1 $450,883 - $538,666	66,502 Added 3821.95%	68,242 $496,000
Q1 2023 May 11, 2023	SELL	$6.78 - $8.1 $837,370 - $1 Million	-123,506 Reduced 98.61%	1,740 $12,000
Q4 2022 Feb 13, 2023	BUY	$5.72 - $9.78 $482,985 - $825,803	84,438 Added 206.92%	125,246 $914,000
Q3 2022 Nov 14, 2022	BUY	$7.24 - $10.31 $7,471 - $10,639	1,032 Added 2.59%	40,808 $315,000
Q2 2022 Aug 11, 2022	BUY	$5.6 - $9.5 $109,849 - $186,352	19,616 Added 97.3%	39,776 $271,000
Q1 2022 May 11, 2022	SELL	$5.46 - $8.13 $88,599 - $131,925	-16,227 Reduced 44.6%	20,160 $160,000
Q4 2021 Feb 10, 2022	BUY	$4.83 - $9.75 $175,749 - $354,773	36,387 New	36,387 $204,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.